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Background. The genetic diversity of human immunodeficiency virus type 1 (HIV-1) raises the question of
whether vaccines that include a component to elicit antiviral T cell immunity based on a single viral genetic clade
could provide cellular immune protection against divergent HIV-1 clades. Therefore, we quantified the cross-clade
reactivity, among unvaccinated individuals, of anti–HIV-1 T cell responses to the infecting HIV-1 clade relative
to other major circulating clades.
Methods. Cellular immune responses to HIV-1 clades A, B, and C were compared by standardized interferon-
g enzyme-linked immunospot assays among 250 unvaccinated individuals, infected with diverse HIV-1 clades,
from Brazil, Malawi, South Africa, Thailand, and the United States. Cross-clade reactivity was evaluated by use
of the ratio of responses to heterologous versus homologous (infecting) clades of HIV-1.
Results. Cellular immune responses were predominantly focused on viral Gag and Nef proteins. Cross-clade
reactivity of cellular immune responses to HIV-1 clade A, B, and C proteins was substantial for Nef proteins (ratio,
0.97 [95% confidence interval, 0.89–1.05]) and lower for Gag proteins (ratio, 0.67 [95% confidence interval, 0.62–
0.73]). The difference in cross-clade reactivity to Nef and Gag proteins was significant ( ).P ! .0001
Conclusions. Cross-clade reactivity of cellular immune responses can be substantial but varies by viral protein.
With an estimated 2.9 million deaths from AIDS and
4.8 million new HIV-1 infections per year worldwide
[1], the development of vaccines against this virus is
an urgent priority. Virus-specific cell-mediated immune
(CMI) responses may not be sufficient to protect against
HIV-1 infection but have been implicated in the control
of HIV-1 replication [2] and will probably play an im-
portant role in any HIV-1 vaccine paradigm [2–5]. Vac-
cination of monkeys to elicit CMI responses, followed
by infection with simian immunodeficiency virus or
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simian-human immunodeficiency virus, results in a
more benign clinical course, compared with that in
unvaccinated controls, including longer survival, lower
viral loads, and better-preserved CD4+ T cell popula-
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tions. Generally, the extent of clinical protection in monkeys
has been shown to correlate with the magnitude of the vaccine-
elicited CMI response at the time of virus challenge [2]. As a
result, a substantial vaccine development effort has been fo-
cused on inducing anti–HIV-1–specific CMI responses, partic-
ularly that of CD8+ cytotoxic T lymphocytes (CTLs).
An important consideration in the development of CMI-
based vaccines is the diversity of HIV-1 worldwide [3, 4]. HIV-
1 is classified into 3 groups (M, O, and N) [6]. The majority
of the HIV-1 circulating globally is type M, which has 9 defined
subtypes, or clades [7]. Of these, clades A, B, and C represent
the large majority (∼86%) of circulating HIV-1 variants [8].
Clade A is prevalent in East Africa; a recombinant variant of
clade A (CRF01_AE) with gag and nef derived from clade A
and env derived from clade E is predominant in Thailand [9].
Clade B is prevalent in Europe, Brazil, the United States, Can-
ada, Australia, and Haiti, as well as in South African men who
have sex with men [10, 11], whereas clade C is predominant
in the southern African subcontinent, Ethiopia, India, and
China [12–14]. It is unclear whether this observed viral diversity
limits broadly reactive CMI responses. This is an important
concern for developing a globally effective vaccine against HIV-
1/AIDS [15], since inadequate cross-reactive CMI responses
may lead to the need to construct several clade-specific vaccines.
It has been shown that clade B–based HIV-1 vaccines can elicit
cross-clade CMI reactivity [16] and that CMI responses from
individuals infected with one clade can lyse target cells infected
with a different clade [17–19]. However, an informative quan-
tification of cross-clade reactivity, by a consistent method in
geographic areas where diverse clades predominate and among
people with diverse HLA types, has not, to our knowledge, been
performed. Therefore, in the present study, we assessed the CMI
responses, among humans infected with diverse HIV-1 clades,
against a series of HIV-1 proteins (Gag, Pol, Nef, Env, Rev, and
Tat) based on near-consensus clade B sequences. We then selected
the 2 proteins, Gag and Nef, that yielded the highest responses
overall and, within each country, assessed cross-reactivity among
clades A, B, and C.
SUBJECTS AND METHODS
Study design. Each study participant signed an informed-con-
sent form before study enrollment. The informed-consent form
described the nature and possible consequences of the study. The
study protocol was approved by the independent ethical review
committee of the universities at each site where the study was
conducted and by the Institutional Review Boards of Harvard
School of Public Health and the Johns Hopkins School of Public
Health, as well as by national authorities, as appropriate. After
informed consent was obtained, HIV-1–positive participants 18–
55 years of age were enrolled at clinic sites in Brazil (Rio de
Janeiro and Sa˜o Paulo), Malawi (Thyolo tea estate), South Africa
(Soweto), Thailand (Bangkok), and the United States (10 sites).
Inclusion criteria were a hematocrit28% obtained before blood
was drawn and a CD4+ T cell count 300 cells/mL. Subsequent
to enrollment, 42 participants were found to have CD4+ T cell
counts !300 cells/mL and were included in the analysis. Exclusion
criteria included positive urine pregnancy test results, breast-feed-
ing, overt evidence of immune compromise, or documented HIV-
1 infection 5 years from the time of screening. Blood samples
were processed, within 12 h of drawing, into peripheral blood
mononuclear cell (PBMC) samples that were frozen using a stan-
dard procedure and shipped in dry ice to a central US laboratory.
Three gene regions were sequenced to determine viral clade
by polymerase chain reaction amplification: gag, nef, and the
V3 loop of env. Since clade determination studies in South Af-
rica and Malawi have reported that 90% of HIV-1 isolates
are clade C [12, 13], only a subset of South African and Ma-
lawian specimens were assayed to confirm the predominant
clade C infection. US participants were men who have sex with
men, among whom clade B infection predominates [20, 21],
and were presumed to be infected with clade B virus. Clade
assignments were made using the National Center for Biotech-
nology Information tool (http://www.ncbi.nlm.nih.gov/projects/
genotyping/formpage.cgi). A homologous clade was defined as
the viral clade type responsible for infection, and heterologous
clades were defined as clades other than the one responsible
for the participant’s infection.
Selection of HIV-1 antigen sequences for study. The T cell
response to each viral antigen was estimated by characterizing
the reactivity of T cells, in PBMCs isolated from each partic-
ipant, to peptide pools derived from near-consensus HIV-1
Gag, Nef, Pol, Rev, and Tat proteins. Peptide pools (synthesized
by the SynPep Corporation, Dublin, CA) contained peptides
20 aa in length, overlapping by 10 aa, that spanned the entire
viral protein. The Pol pools used in some assays contained 15-
aa peptides overlapping by 11 aa. Because of the size of the
Pol protein, Pol peptides were divided into 2 pools, Pol-1 and
Pol-2, each representing half of the protein. The Gag and Nef
amino acid sequences of clades A, B, and C were obtained from
primary virus isolate sequences in the Los Alamos HIV-1 da-
tabase that were as close as possible to the consensus sequence
in that clade type [22]. Percentage homology in the identity of
amino acid sequences was determined for Gag and Nef proteins
from pairwise alignments by use of BioEdit [23] (table 1). Com-
parisons of these prototypical amino acid sequences with each
other and with consensus sequences are shown in the Appendix,
which appears only in the electronic edition of the Journal.
Measurement of T cell responses. Anti–HIV-1–specific T cell
responses were quantified using an enzyme-linked immunospot
(ELISPOT) assay of interferon (IFN)–g secretion that has been
shown to have high correlations with other methods, such as
intracellular cytokine staining, tetramer staining, and the classical
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Table 1. Percentage amino acid identity matrices for clade A, B, and C Gag and Nef proteins.
Protein, clade
Amino acid identity, %, with clade
Aa Bb Cc Consensus A Consensus B Consensus C
Gag
A 100 83.6 (83.9) 81.3 (83.7) 92.5 (92.5) 84.4 (84.7) 84.1 (85.5)
B 100 82.2 (84.5) 85.8 (86.5) 98.6 (98.6) 85.6 (86.9)
C 100 83.7 (86.1) 83.0 (85.3) 92.5 (93.6)
Consensus A 100 86.4 (87.1) 87.3 (88.7)
Consensus B 100 86.2 (87.6)
Consensus C 100
Nef
A (SE8891) 100 73.6 (77.9) 76.5 (78.8) 93.6 (93.6) 80.5 (81.3) 81.1 (82.3)
B (JRFL) 100 71.4 (77.8) 75.4 (79.9) 87.9 (92.2) 79.7 (83.9)
C (IN21068) 100 79.0 (81.4) 74.8 (77.8) 83.6 (87.4)
Consensus A 100 83.4 (84.3) 85.0 (86.2)
Consensus B 100 86.9 (87.3)
Consensus C 100
NOTE. Percentage amino acid sequence identities in Gag (top) and Nef (bottom) proteins were determined from
pairwise alignments, by use of BioEdit [23]. The first values given were calculated with alignment gaps considered as
mismatches, and the second values (in parentheses) were calculated without assessing gap penalties.
a Gag peptides were based on the sequences of HIV 90CF4071 (GenBank accession no. AF197341), and Nef peptides
were based on the sequences of HIV SE8891 (GenBank accession no. AF069373).
b The HIV CAM-1 sequence (GenBank accession no. D10112) was used for Gag, and the HIV JR-FL sequence
(GenBank accession no. U63632) was used for Nef.
c Virus HIV 96ZM751 (GenBank accession no. AF286225) was used for Gag, and virus HIV IN21068 (GenBank
accession no. AF067155) was used for Nef.
chromium-51 release assay. The ELISPOT assay has been used
as a reliable tool for quantifying both HIV-1–specific and gener-
al CMI responses [24–28]. The assay measures antigen-specific
memory T cells that secrete IFN-g upon exposure to antigenic
peptides presented by antigen-presenting cells. PBMC samples
were placed in 96-well plates with well membranes of polyvi-
nylidene fluoride (Millipore) coated with anti–human IFN-g
monoclonal antibody (MAbTech). Cells at cells/well and52 10
cells/well, in duplicate, were incubated overnight in a51 10
37C, 5% CO2 incubator with peptide pools diluted to an ∼2.5
mg/mL final concentration per peptide. After washing, bound
IFN-g was detected with biotinylated anti–IFN antibody (MAb-
Tech), followed by alkaline phosphatase–conjugated anti-biotin
antibody (Vector Laboratories) and visualization using 5-bromo-
4-chloro-indolyl-phosphatase/nitroblue tetrazolium (BCIP/NBT)
substrate (Pierce). IFN-g–expressing cell spots were enumer-
ated with a digital imager and automated counting system (Auto-
Immun Diagnostika). A positive response was identified as a
minimum of 55 IFN-g–expressing cells/million PBMCs with
values at least 4-fold higher than in nonantigen control wells.
This criterion was previously determined by statistical assay
validation to result in a !1.0% false-positive rate (authors’ un-
published data). Results were expressed as the number of IFN-
g–expressing cells per million PBMCs.
Statistical analysis. It was anticipated that ELISPOT re-
sponses to stimulation by Gag, Nef, and Pol proteins would be
the most robust among the various antigens considered [29,
30]. Accordingly, the ELISPOT summaries of responses to Gag,
Nef, and Pol were compared with the corresponding summaries
of responses to Rev and Tat, by use of 2-tailed paired t tests
on log-transformed data (for comparing geometric means) and
exact McNemar’s tests (for comparing response proportions).
To reduce the potential for “false discoveries,” within each analy-
sis, the 8 P values (Gag, Nef, Pol-1, and Pol-2 vs. Rev and Tat)
were assessed for statistical significance after a multiplicity ad-
justment [31]. Multiplicity-adjusted P values !.05 were con-
sidered statistically significant.
The ELISPOT responses for each individual are the product
of lymphocyte stimulation probabilities that depend on the an-
tigen, the infecting clade, and the number of cytotoxic T lym-
phocytes per million PBMCs. The ELISPOT assays quantified
the ability of T cells in HIV-1–infected individuals, upon stim-
ulation with Gag- and Nef-specific peptides, to elicit cellular
immune responses from a heterologous clade. For each par-
ticipant, we calculated the ratio of ELISPOT responses to a
heterologous clade versus ELISPOT responses to the homol-
ogous (infecting) clade. The geometric mean of these ratios
over all individuals in a population provides an estimate of the
overall ratio of stimulation probabilities for the population,
specific to the gene, the clade of infection, and the stimulating
clade. We refer to these probability ratios as “cross-clade reac-
tivity ratios” and calculated them using STATA (version 8; Sta-
tacorp). Ratios closer to 1 indicate greater cross-clade reactivity,
and ratios closer to 0 indicate less cross-clade reactivity. For
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Table 2. Characteristics of the 250 study participants.
Characteristic
Value in participants from
Brazil
( )np 55
Malawi
( )np 46
South Africa
( )np 38
Thailand
( )np 75
United States
( )np 37
Age, median (95% CI), years 31 (30–33) 34 (29–37) 30 (28–32) 29 (927–31) 44 (41–47)
Sex, % women 49 43 89 64 0
Race, %
Asian 2 0 0 100 NA
Black 15 100 100 0 NA
White 67 0 0 0 NA
Other 16 0 0 0 NA
CD4+ T cell count, median (95% CI), cells/mL 493 (424–545) 432 (389–457) 611 (509–718) 351 (302–405) 668 (516–908)
Plasma viral load, median (95% CI), 1000s of copies/mL 16 (12–26) 74 (3–118) 8 (4–26) 30 (19–59) 0.9a (0.4–3)
Risk behavior during past 10 years, % of participants
Injection drug use 0 NA 0 6 NA
Heterosexual contact 67 NA 96 81 NA
Men had sex with men 33 NA 4 8 NA
Sex work 0 NA 0 5 NA
NOTE. CI, confidence interval; NA, not available.
a Of US participants, 50% were receiving antiretroviral therapy and 15% had received antiretroviral therapy.
each country, Wilcoxon signed rank tests were used to test for
differences between anti-Gag and anti-Nef cross-clade ratios,
by use of the aforementioned multiplicity adjustment [32, 33].
RESULTS
Study participants. Two hundred fifty-four HIV-1–positive
participants consented and were enrolled in the study. Four par-
ticipants (1.6%) with mock control ELISPOT values200 IFN-
g–expressing cells/million PBMCs were excluded. Characteristics
of the 250 participants are shown in table 2. ELISPOT results
were available for 209 participants for all 5 HIV-1 antigens.
Clade type. All 10 tested Gag and Nef sequences from Ma-
lawian participants were identified as clade C. The clade types
of the viral isolates obtained from the 19 South African par-
ticipants were identified as 95% ( ) clade C and 5%np 18
( ) clade B, for both Gag and Nef. Clade typing amongnp 1
Brazilian participants was based on 3 gene sequences: gag (n
p19), nef ( ), and V3 env ( ). Among Braziliannp 29 np 55
participants, clade types were as follows: 69% clade B, 15%
clade C, 8% clade B/D, and 8% clade B/F1 recombinants, on
the basis of gag sequencing; 83% clade B, 7% clade C, and 3%
each of clade F1, A1/B, and B/F2 recombinants, on the basis
of nef sequencing; and 78% clade B, 15% clade F, and 5% clade
C, on the basis of V3 env sequencing. Similarly, clade typing
among Thai participants was based on 3 gene sequences: gag
(np 10), nef ( ), and V3 env ( ). Clade typesnp 22 np 50
among Thai participants were 100% CRF01_AE, on the basis
of gag sequencing; 82% CRF01_AE and 18% clade B, on the
basis of nef sequencing; and 90% CRF01_AE and 10% clade
B, on the basis of V3 env sequencing, consistent with previous
reports [33].
Comparison of cellular immune responses to clade B HIV-1
proteins. Quantitative ELISPOT responses (figure 1) to Gag, Nef,
Pol-1, and Pol-2 were higher than those to Rev and Tat, for the
overall study population ( ) and within each country (PP ! .0001
! .04). The proportions of participants with positive ELISPOT
responses to Gag (95%), Nef (84%), Pol-1 (82%), and Pol-2 (75%)
were higher than those for Rev (28%) or Tat (17%), for the overall
study ( ) and within each country ( ), except inP ! .0001 P ! .0001
the United States ( ), which contributed only 15 participantsP ! .13
to this analysis (data not shown). The proportion of the study
population that consisted of ELISPOT responders to clade B Gag
or Nef was 96%. In countries with non–clade B founder viruses,
the proportion of the study population responding to clade B Gag
and/or Nef proteins was 99% in Thailand, 100% in Malawi, and
95% in South Africa (data not shown).
ELISPOT responses to peptide pools based on the clade B
89.6P Env protein were assessed for a subset of participants
(data not shown). The anti-Env responses were lower than the
anti-Gag ( ), anti-Nef ( ), and anti-Pol ( )P ! .0001 P ! .005 P ! .02
responses. Additional experiments in a subset of individuals
( ) were performed to determine the relative contribu-np 44
tions of CD8+ versus CD4+ T cell responses against the Gag
and Nef antigens. These responses were measured by flow cy-
tometry detection of intracellular IFN-g production by antigen-
stimulating cells, by use of the same peptide pools as those
used for the ELISPOT assays. All of the participants exhibited
strong CD8+ T cell responses, and the majority did not have
detectable CD4+ T cell responses. Among participants with both
CD8+ and CD4+ T cell responses, the CD8+ T cell response was
always greater than the CD4+ T cell response. No participant
had an antigen-specific CD4+ T cell response in the absence of
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Figure 1. Anti–HIV-1 T cell responses to clade B antigens. Responses are shown as geometric means of interferon (IFN)–g enzyme-linked immunospot
(ELISPOT) assay responses among 209 HIV-1–infected participants, expressed as the no. of IFN-g–expressing cells per million PBMCs
a CD8+ T cell response. These observations are consistent with
reports that chronically HIV-1–infected humans exhibit a pre-
dominantly CD8+ T cell response against HIV-1 antigens [34].
In the same subset of 44 participants, the correlation between
cellular immune responses measured by IFN-g ELISPOT and
IFN-g intracytokine staining in the CD8+CD3+ subpopulation
was ( ).rp 0.72 P ! .0001
Evaluation of cross-clade CMI responses. Figure 2 shows
log10-transformed ELISPOT responses to HIV-1 Gag and Nef
proteins. The 45 line in each graph represents the points for
which ELISPOT responses to stimulation by the clade proteins
represented on the X-axis are quantitatively the same as re-
sponses to stimulation by the clade proteins represented on the
Y-axis. The data points comparing responses to one clade with
responses to another clade cluster relatively tightly around the
45 identity line. The slopes of the regression lines for each of
the graphs in figure 2 were calculated using the no-constant
option, so that the regression line originates at the 0 point on
both axes and is analogous to the ratios shown in table 3. The
slopes of the regression lines (figure 2) were very close to 1.0,
which is the slope of the 45 identity line; therefore, regression
lines are not shown.
A quantitative assessment of the ratios of ELISPOT responses
to the 3 major HIV-1 clades tested in the present study is
presented in table 3. The founder clade in each country was
used in the denominator of the ratio, and each of the other 2
clades was used (separately) in the numerator. The geometric
mean ratios of cellular immune responses in the entire study
population were 0.93 (95% confidence interval [CI], 0.82–1.04)
against clade A Gag versus clade B Gag, 0.99 (95% CI, 0.90–
1.10) against clade C Gag versus clade B Gag, 0.97 (95% CI,
0.87–1.09) against clade A Nef versus clade B Nef, and 0.98
(95% CI, 0.87–1.10) against clade C Nef versus clade B Nef.
The geometric mean of cross-clade ratios was calculated in-
dependently for each country. The data indicate various degrees
of lower CMI responses to heterologous clades in comparison
with homologous clades, depending on the population and pro-
tein evaluated. The lowest cross-clade reactivity was observed for
the anti-Gag responses among South African and Malawian par-
ticipants (clade C founder), but their anti-Nef CMI responses
did not show cross-clade attenuation. When Gag and Nef cross-
clade reactivity was paired and the higher of the pair selected to
represent the cross-clade reactivity of each clade comparison, the
lowest cross-clade reactivity was noted among US participants,
for the ratio of clade C versus clade B (0.65). The second lowest
cross-clade reactivity, 0.73, was observed among Malawians for
the ratio of clade A versus clade C and among Thais for the ratio
of clade B versus clade A.
The differences between the anti-Gag and anti-Nef cross-
clade reactivities shown in table 3 were evaluated by ranking
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Figure 2. Cross-clade reactivity of anti–HIV-1 T cell immune responses against HIV-1 Gag and Nef (see text). Values on the axes represent the
log10 no. of interferon (IFN)–g–expressing cells per million peripheral blood mononuclear cells. The slopes of the regression lines calculated using the
no-constant option, so that the regression line originates at the 0 point on both axes, are as follows: clade C Gag vs. clade B Gag, 0.991 (95%
confidence interval [CI], 0.977–1.007); clade A Gag vs. clade B Gag, 0.978 (95% CI, 0.958–0.993); clade C Nef vs. clade B Nef, 0.988 (95% CI, 0.970–
1.007); and clade A Nef vs. clade B Nef, 0.984 (95% CI, 0.966–1.001).
the cross-clade reactivity for each study subject, by use of a
signed rank test. Anti-Nef cross-clade reactivity was statistically
significantly higher than anti-Gag cross-clade reactivity (P !
). The proportion of participants with positive ELISPOT.0001
responses to all 3 clade (A, B, and C) Gag proteins was 90%,
to all 3 clade Nef proteins was 72%, and to either all 3 clade
Gag or all 3 clade Nef proteins was 94%.
DISCUSSION
Most of the HIV-1 vaccine approaches that are currently being
tested in human clinical trials include a component that is fo-
cused on eliciting antiviral CMI responses. Although there is
a substantial body of evidence suggesting that vaccine-induced
CMI responses possibly could control infection and prevent—
or significantly delay—progression of AIDS, it is not clear
whether vaccine antigens can be defined that are capable of
providing broad coverage against the genetically diverse virus
variants prevalent throughout the world. Therefore, we have
studied this issue by evaluating which HIV-1 antigens appear
to be the most broadly recognized by the CMI response in
participants infected with such genetically diverse viruses. We
then quantified the extent of cross-reactive responses for 2 of
these antigens. The results suggest that broadly effective vac-
cine-induced CMI responses may be feasible and provide guid-
ance for the selection of vaccine antigens.
Some previous studies sharing these objectives have identi-
fied Gag, Pol, Nef, and Env proteins as the most common HIV-
1 antigen targets for CTL responses, whereas other studies have
emphasized the importance of Rev and Tat responses [35]. In-
vestigators have also reported that cross-clade responses are
either limited [4] or common [18, 36–39]. Explanations for
these apparently conflicting findings include small sample size
and a focus on single epitopes; different assay methodologies
(e.g., cytokine detection vs. cytotoxic assays) that may measure
different response attributes or have different quantitative po-
tential also contribute to the apparent discrepant conclusions.
Previously conducted studies were restricted to a maximum of
2 countries, and the selection of HIV-positive participants was
inconsistent and often varied by geographic region. All of the
studies provided a qualitative assessment of cross-clade reac-
tivity; however, a quantitative assessment of cross-clade reac-
tivity is necessary for designing HIV-1 vaccines. We therefore
conducted a more systematic and quantitative assessment of
the cross-clade reactivity of CMI responses, by use of a single
study protocol with standardized clinical and laboratory pro-
cedures at each study site and centralized IFN-g ELISPOT as-
says conducted in 1 laboratory to ensure consistency.
Our data show that HIV-1–infected individuals have quan-
titatively stronger CMI responses to Gag, Nef, and Pol, in com-
parison with responses to clade B Rev and Tat proteins, within
each of the 5 countries studied. The ratio of ELISPOT responses
to stimulation by heterologous clade A, B, and C Gag and Nef
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Table 3. Ratios of cellular immune responses against HIV-1
Gag and Nef proteins, for heterologous clades versus homologous
clades, among 250 HIV-1–infected participants.
Country, clade
comparison
Immune response ratio,
geometric mean (95% CI)
Gag Nef
Brazila ( )np 55
A vs. B 0.77 (0.64–0.91) 0.89 (0.74–1.08)
C vs. B 0.82 (0.68–0.98) 0.95 (0.78–1.14)
Malawib ( )np 45
A vs. C 0.50 (0.39–0.62) 0.73 (0.57–0.94)
B vs. C 0.73 (0.60–0.88) 1.02 (0.83–1.24)
South Africab ( )np 38
A vs. C 0.47 (0.38–0.57) 0.90 (0.65–1.24)
B vs. C 0.51 (0.40–0.66) 1.04 (0.87–1.24)
Thailandc ( )np 75
B vs. A 0.64 (0.50–0.81) 0.73 (0.58–0.91)
C vs. A 0.53 (0.43–0.65) 0.92 (0.72–1.19)
United Statesd ( )np 37
A vs. B 0.63 (0.48–0.81) 0.89 (0.70–1.12)
C vs. B 0.65 (0.55–0.77) 0.63 (0.42–0.95)
NOTE. Values in the table represent the geometric means of enzyme-
linked immunospot (ELISPOT) response ratios against Gag or Nef for each
study population. For each participant, the ratio of ELISPOT responses to one
clade vs. another was calculated. The geometric mean of the ratio for the
study population was then calculated. For each country, the ratios of heter-
ologous clades relative to the homologous clade that is predominant in that
country are shown.
a HIV-1 clade frequencies are as follows: clade B, 78%; clade F, 15%; clade
C, 5%.
b Clade C is the founding HIV-1 clade.
c HIV-1 clade frequencies are as follows: CRF01_AE, 90%; clade B, 10%.
d Clade B is the founding HIV-1 clade.
antigens versus responses to the infecting virus clade that is
predominant in a country indicated substantial cross-reactiv-
ities. The lowest level of cross-clade reactivity was apparent
among southern African participants, for anti-Gag responses, but
this lower cross-clade reactivity was not observed for anti-Nef
responses. Indeed, anti-Nef cross-clade reactivity exceeded that
of anti-Gag. These results suggest that the anti-Nef response may
likely be focused on the internal region that is highly conserved
across clades. The cross-clade ratios were not influenced by the
CD4+ T cell count, plasma viral load, age, or sex of the partic-
ipants (data not shown).
The relatively high degree of cross-clade immune responses
that we have measured probably occurs in large part as a result
of the substantial protein sequence conservation observed for
Gag and Nef. Pol is more conserved (190%) than Gag (180%)
and Nef (170%) across clades A, B, and C. Cross-clade reactivity
to Pol, other than using clade B reference peptides in figure 1,
was not further assessed in this study. Its higher degree of con-
servation would likely mean that anti-Pol cross-clade reactivity
would be similar to, or higher than, the observed anti-Gag and
anti-Nef cross-clade reactivity. Preliminary epitope mapping for
a subset of subjects by use of 9mer and 15mer peptides repre-
senting clade B Gag and Nef indicated that there were 2–13
epitopes recognized per participant tested. The recognized epi-
topes were distributed throughout the length of the Gag and Nef
protein and varied from individual to individual. The recognized
epitopes appeared to contribute to cross-clade reactivity because
(1) peptide sequences were identical between clades, (2) peptide
sequences differed by only 1 or 2 conservative amino acid sub-
stitutions between clades, or (3) peptide sequences differed by
multiple or nonconservative substitutions. The first of these in-
stances, and sometimes the second, would be expected to yield
equivalent and biologically significant affinity associations be-
tween T cells and target cells, irrespective of clade. By contrast,
the last instance could result in lower affinity associations and,
therefore, could mediate limited biological activity. Extensions
of these observations are an important corollary to the present
study and will be pursued for a better understanding of the basis
for cross-clade immunity.
Either Gag or Nef cross-clade responses can be somewhat low
in some cases, but at least 1 tends to be high in any given cir-
cumstance. Therefore, the likelihood of producing cross-clade
responses is greater with both antigens than with either alone
and would be further enhanced by the inclusion of Pol. It is
logical to project from these results that the most effective CTL-
based vaccine would be one that drives responses to as many
epitopes as possible, as well as to the most-conserved deter-
minants, to increase the probability that vaccinated individuals
will have potential matches against epitopes within viruses they
may encounter. Such broad responses could also exert multiple
immunological pressures against the virus and help minimize
the selection of escape mutants. In conclusion, our results show
that substantial cross-clade CMI responses exist across the 3
clades that represent most HIV-1 infections worldwide, re-
gardless of infecting virus genotype. This observation suggests
that similar CMI responses elicited by a vaccine composed of
antigens based on a single clade—especially for Gag, Pol, and
Nef—could possibly be broadly effective and warrant further
testing in clinical trials.
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